Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

The companion diagnostics sector is rapidly transforming the healthcare landscape by enabling more precise and personalized treatment options. This market is growing at a remarkable pace, driven by advances in targeted therapies and diagnostic technologies. Let’s explore the current market size, key growth drivers, evolving segments, innovation trends, leading companies, and regional dynamics shaping the future of companion diagnostics.

Companion Diagnostics Market Size and Projected Growth

The companion diagnostics market has witnessed significant expansion recently. It is projected to increase from $8.69 billion in 2025 to $10.54 billion in 2026, reflecting a substantial compound annual growth rate (CAGR) of 21.3%. This impressive growth during the past years can be linked to the rise in targeted cancer therapies, the growth of oncology clinical trials, closer collaborations between pharmaceutical and diagnostics companies, increasing cancer incidence, and the surge in regulatory approvals for companion diagnostic tests.

Looking ahead, the market is expected to reach $22.7 billion by 2030, maintaining a strong CAGR of 21.1%. This future expansion will be driven by rising demand for personalized treatment selection, increasing investments in precision medicine, growth in immuno-oncology pipelines, adoption of AI-powered diagnostic interpretation, and stronger regulatory focus on co-development of diagnostics and drugs. Key trends anticipated to dominate this period include widespread use of precision oncology diagnostics, deeper integration of companion diagnostics in drug development, growing reliance on next-generation sequencing (NGS) platforms, expansion of biomarker-guided therapies, and heightened emphasis on individualized medicine.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7038&type=smp

Main Factors Encouraging Growth in the Companion Diagnostics Market

One of the primary growth drivers for the companion diagnostics market is the rising number of targeted therapies. These therapies focus on specific cancer cell characteristics to prevent tumor growth and spread. Unlike traditional chemotherapy, targeted treatments circulate throughout the body but act more precisely, often resulting in fewer side effects. Biomarker-based companion diagnostic testing has become crucial in delivering personalized cancer care.

For instance, in February 2024, the Personalized Medicine Coalition, a US healthcare organization, reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, a significant increase from 6 approvals in 2022. This surge in approvals underscores the rapid development of targeted therapies, which in turn propels the companion diagnostics market forward.

Companion Diagnostics Market Segmentation Overview

This report divides the companion diagnostics market into distinct categories for a clearer understanding:

1) By Product and Service: Assays, Kits and Reagents, Software and Services

2) By Technology: Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), In Situ Hybridization (ISH), Immunohistochemistry (IHC)

3) By Indication: Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Melanoma

4) By End-User: Pharmaceutical and Biopharmaceutical Companies, Reference Laboratories, Contract Research Organizations

Further subsegments include assays such as PCR assays, IHC assays, NGS assays, and ISH assays; kits and reagents including diagnostic kits, detection reagents, and control reagents; as well as software and services covering data analysis software, interpretation software, custom development, and consulting/support services.

Access The Complete Companion Diagnostics Market Report:

https://www.thebusinessresearchcompany.com/report/companion-diagnostics-global-market-report

Innovation Trends Shaping the Future of Companion Diagnostics

Leading players in the companion diagnostics space are forging partnerships to develop cutting-edge solutions that enhance personalized treatment and improve patient results. These collaborations accelerate the creation and market introduction of companion diagnostics, especially for hematology and oncology applications.

A notable example occurred in January 2024 when Agilent Technologies, a US-based provider of laboratory instruments and services, signed an agreement with pharmaceutical company Incyte. This collaboration leverages Agilent’s expertise in companion diagnostic development to support Incyte’s hematology and oncology portfolios. The partnership helps expand Agilent’s diagnostic offerings with new biomarkers while enabling Incyte to benefit from Agilent’s capabilities in assay design, regulatory compliance, and commercialization for clinical trials and companion diagnostic approvals in the US and Europe.

Major Players Competing in the Companion Diagnostics Industry

Key companies that dominate the companion diagnostics sector include F Hoffmann-La Roche Ltd., Agilent Technologies Inc., Qiagen NV, Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Amoy Diagnostics Co. Ltd., Danaher Corporation, Guardant Health Inc., Illumina Inc., Myriad Genetics Inc., Siemens Healthcare GmbH, Almac Group, Caris Life Sciences, Cepheid Inc., Diaceutics plc, Epic Sciences Inc., Foundation Medicine Inc., Genomic Health Inc., Grail Inc., Hologic Inc., HTG Molecular Diagnostics Inc., Inivata Ltd., Invivoscribe Inc., MolecularMD Corporation, Natera Inc., NeoGenomics Laboratories Inc., Personal Genome Diagnostics Inc., Precision Therapeutics Inc., Prometheus Laboratories Inc., Sysmex Corporation, and Ventana Medical Systems.

Geographical Landscape of the Companion Diagnostics Market

In 2025, North America held the largest share of the companion diagnostics market. The overall market analysis includes regions such as Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East, and Africa. Among these, North America remains the key player in market size, although other regions are steadily expanding their presence and investment in companion diagnostics.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model